PDF
(Download)
|
- Maca (Lepidium meyenii, Brassicaceae)
- Sexual Dysfunction
- Antidepressants
|
Date:
11-13-2015 | HC# 051554-532
|
Re: Maca Helps Improve Some Symptoms of Antidepressant-induced Sexual Dysfunction in Women
Dording
CM, Schettler PJ, Dalton ED, et al. A double-blind placebo-controlled trial of
maca root as treatment for antidepressant-induced sexual dysfunction in women. Evid Based Complement Alternat Med.
2015;2015:949036. doi: 10.1155/2015/949036.
A
common adverse side effect associated with the selective serotonin reuptake
inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) is
antidepressant-induced sexual dysfunction. Many postmenopausal women turn to
complementary and alternative medicine to treat antidepressant-induced sexual
dysfunction. Maca (Lepidium meyenii, Brassicaceae)
root is traditionally used by Andean people for nutrition and to enhance
fertility. Clinical trials with maca have shown a
statistically significant improvement in several symptoms related to
perimenopause and menopausal women, and a few other published papers have
documented improvement in libido in women, including the previously published
open-label trial by the same authors in which they concluded that 3 g/day of
maca root increased sexual activity and improved sexual experiences.1 The purpose of this double-blind,
placebo-controlled study was to validate the results of the open-label study.
Women
(n = 45; mean age, 41.5 years) with depression in the remission state and
having antidepressant-induced sexual dysfunction were recruited from the
Depression Clinical and Research Program; Boston, Massachusetts. Included
patients met the following criteria: score of ≤ 9 on the 17-item Hamilton
Rating Scale for Depression (HAM-D-17) and a score of ≤ 9 on the Hamilton
Rating Scale for Anxiety (HAM-A) to indicate remission; taking a stable dose of
an SSRI, venlafaxine, or a tri/heterocyclic antidepressant for the treatment of
depression for at least 4 weeks; suffering from clinically significant arousal
dysfunction or orgasmic dysfunction for at least 4 weeks, and the dysfunction
had to have emerged subsequent to the use of the currently prescribed
antidepressant; partaking in some regular sexual activity (i.e., masturbation,
oral sex, intercourse) at least twice monthly prior to antidepressant use; and must
have been willing to continue sexual activity at least once weekly for the
duration of the study.
Patients
were excluded for the following criteria: diagnosed with a sexual disorder in
the past; were currently receiving another treatment for sexual dysfunction; were
experiencing sexual dysfunction due to a general underlying medical condition; had
experienced recent major relationship changes or turmoil unrelated to the sexual
dysfunction; or had any other general health problems or social situations that
might have influenced sexual dysfunction or its treatment.
Patients
received either 1500 mg maca root (manufacturer and form not provided other
than to say "Peruvian manufacturer") or placebo 2x/day for 12 weeks.
Sexual function was evaluated with the Massachusetts General Hospital-Sexual
Functioning Questionnaire (MGH-SFQ) and the Arizona Sexual Experience Scale (ASEX).
Degree and improvement in antidepressant-induced sexual dysfunction were assessed
with the Clinical Global Impression-Severity and Clinical Global
Impression-Improvement scales (CGI-S and CGI-I, respectively). Depression and
anxiety were monitored with the 28-item HAM-D, the 14-item HAM-A, and the
Kellner's Symptoms Questionnaire (SQ). Blood was drawn to assess estradiol, progesterone,
prolactin, and testosterone levels (timing not reported).
The
mean change in ASEX and MGH-SFQ was not significantly different between groups.
When the data were subgrouped by premenopause vs. postmenopause, there were
still no significant differences between groups on the sexual function
questionnaires. However, the maca group compared with the placebo group had higher
remission rates on the ASEX (9.5% vs. 4.8%, respectively) and the MGH-SFQ (30%
vs. 20%, respectively) (P values not reported). When the remission rate data
were analyzed by premenopause vs. postmenopause, it was apparent that the
higher remission rates occurred in postmenopausal women. In contrast,
premenopausal women had no significant difference in remission rates between
treatment groups on both sexual function questionnaires.
Only
postmenopausal women taking maca had an improvement in orgasm compared with
placebo (P value not reported) and only premenopausal women taking maca had an
improvement in arousal compared with placebo (P value not reported). There was
a significant correlation between testosterone levels at endpoint and sexual
functioning on the ASEX in the maca group (P = 0.042), and a trend toward
significance on the MGH-SFQ (P = 0.057). There were no significant differences
in the other hormones, including estrogen levels, suggesting to the authors
that the difference seen in the postmenopausal group was due more to advanced age
than menopausal status.
Maca
root was well tolerated. Three patients in the maca group discontinued for
flu-like symptoms and vomiting; however, the authors do not attribute these
adverse events to maca use. The authors report that the CGI-S, CGI-I, 28-item
HAM-D, 14-item HAM-A, and SQ were conducted; however, they do not report the
findings from these tests.
The
authors conclude that maca root may alleviate antidepressant-induced sexual
dysfunction. They acknowledge that a larger study is needed to confirm the
findings, and they report that they are currently conducting a follow-up study.
The data indicate that the mechanism of maca root may involve an alteration in
androgen levels. It is well known that testosterone levels affect sexual function/dysfunction,
so the proposed mechanism of action for maca root is plausible. Previous maca root research demonstrates a lowering of follicle-stimulating
hormone (FSH) and an increase in estrogen. The authors admit to many
limitations, including the relatively small sample size, reliance on patient
self-reporting, and the use of chemiluminescence assays that are known to have
trouble detecting lower levels of testosterone in women. Additionally, they
suggest future studies should include liver function tests to determine the effect
of high-dose maca supplementation on liver function. In future studies, the
authors should publish the product name and manufacturer so that the results
can be replicated. Also, the authors evaluated many endpoints but did not
publish the data without explaining why. This is a disclosure concern.
—Heather S. Oliff,
PhD
Reference
The American Botanical Council provides this review
as an educational service. By providing
this service, ABC does not warrant that the data is accurate and correct,
nor does distribution of the article constitute any endorsement of the
information contained or of the views of the authors.
ABC does not authorize the copying or use of the
original articles. Reproduction of
the reviews is allowed on a limited basis for students, colleagues,
employees and/or members. Other uses
and distribution require prior approval from ABC.
|
|
1Dording CM, Fisher
L, Papakostas G, et al. A double-blind, randomized, pilot dose-finding study of
maca root (L. meyenii) for the
management of SSRI-induced sexual dysfunction. CNS Neurosci Ther. 2008;14(3):182-191.
|